Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

IN THE NAME OF GOD By: Dr malek. References Am J Clin Pathol. 2008;130(5): © 2008 American Society for Clinical Pathology Bryant J, Picot J,

Advertisements

Figure 1 Estimated annual percentages of new

Copyright © 2002 American Medical Association. All rights reserved.

Figure 1. Serum creatinine trend in the patient

From: Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction in Childhood Cancer Survivors: A Model-Based Estimation of the Clinical.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 3 Risk-adapted and response-adapted

Figure 5 Schematic illustration of different clinical trial designs

Figure 2 Three-step approach to the assessment and management

Joerg Herrmann, MD, Amir Lerman, MD, Nicole P

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Figure 3 Care needs of patients with advanced-stage cancer

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Algorithm for the determination of the clinical

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Clinical vignette and putative causal relationships

Nat. Rev. Cardiol. doi: /nrcardio

Fig. 2. Evidence-based medication prescriptions

Figure 5 Palliative-care-referral patterns

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Frequency and overlap of alterations

Figure 2 Variations between planned and delivered doses of radiation

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

Patient selection. *This category included 10 patients with suspected tachyarrhythmia, 9 treated for cancer with cardiotoxic cytostatics and/or transthoracic.

Figure 3 Determination of the primary site

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Figure 1 Gene-expression quantification methods

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.171 Figure 5 Proposed algorithm for the management of cardiotoxicity in patients receiving anthracyclines Figure 5 | Proposed algorithm for the management of cardiotoxicity in patients receiving anthracyclines. Cardiac function can be monitored using serum troponin levels and/or echocardiography; findings of initial investigations dictate the necessary follow-up intervals. In practice, adherence to this type of follow-up regimen is inconsistent. Frequent testing of asymptomatic patients might lead to many 'false positives' and the resultant anxiety and possible additional unnecessary interventions and associated morbidity and costs. This, and similar algorithms have not been validated and their clinical utility is currently uncertain. ACEI, angiotensin-converting-enzyme inhibitor; BB, β-blocker; CT, chemotherapy; ECHO, echocardiogram; LVD, left-ventricular dysfunction; TnI, troponin I. Modiﬁed with permission from Curigliano, G. et al. Ann. Oncol. 23, S55–S66 (2012)68. Modified with permission from Curigliano, G. et al. Ann. Oncol. 23, S55–S66 (2012) Zagar, T. M. et al. (2015) Breast cancer therapy-associated cardiovascular disease Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.171